Cerus appoints Dean Gregory to Board of Directors

CERUS CORP

Dean Gregory appointed to Cerus Board, effective July 1, 2024; term expires at 2027 annual meeting.
Gregory is former President, Global Commercial Operations at Fresenius Kabi, with 30+ years in transfusion medicine.
He receives initial RSU of 60,000 shares (3-year vest) and annual cash retainer of $45,000 under director policy.
Gregory's industry expertise expected to support INTERCEPT Blood System expansion and manufacturing capacity growth.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dean Gregory

Director

CERS · CERUS CORP

Effective: 2024-07-01
Filed: July 2, 2024, 7:59 PM ET

the Board extended an offer to join the Board to Dean Gregory, and on July 1, 2024, Mr. Gregory accepted such offer to join the Board, effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dean Gregory was appointed as Director at CERUS CORP.

Action: appointed
Role: Director

Exact text from the filing

the Board extended an offer to join the Board to Dean Gregory, and on July 1, 2024, Mr. Gregory accepted such offer to join the Board, effective July 1, 2024.

View on SEC.gov

CERUS CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-080426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.